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Prognosis and Reclassification by YKL-40 in Stable Coronary Artery
Disease
Jakob Schroder, MD; Janus Christian Jakobsen, MD, DMSc; Per Winkel, MD, DMSc; Jørgen Hilden, MD, DMSc; Gorm Boje Jensen, MD,
DMSc; Ahmad Sajadieh, DM, DMSc; Anders Larsson, MD, PhD; Johan €Arnl€ov, MD, PhD; Marina Harutyunyan, MD, PhD;
Julia S. Johansen, MD, DMSc; Erik Kjøller, MD, DMSc; Christian Gluud, MD, DMSc; Jens Kastrup, MD, DMSc
Background-—The inflammatory biomarker YKL-40 has previously been studied as a potential risk marker in cardiovascular disease.
We aimed to assess the prognostic reclassification potential of serum YKL-40 in patients with stable coronary artery disease.
Methods and Results-—The main study population was the placebo group of the CLARICOR (Effect of Clarithromycin on Mortality
and Morbidity in Patients With Ischemic Heart Disease) trial. The primary outcome was a composite of acute myocardial infarction,
unstable angina pectoris, cerebrovascular disease, and all-cause mortality. We used Cox proportional hazards regression models
adjusted for C-reactive protein level and baseline cardiovascular risk factors. Improvement in prediction by adding serum YKL-40 to
the risk factors was calculated using the Cox-Breslow method and c-statistic. A total of 2200 patients were randomized to placebo,
with a follow-up duration of 10 years. YKL-40 was associated with an increased risk of the composite outcome (hazard ratio per
unit increase in (YKL-40) 1.13, 95% CI 1.03–1.24, P=0.013) and all-cause mortality (hazard ratio 1.32, 95% CI 1.17–1.49,
P<0.0001). Considering whether a composite-outcome event was more likely to have, or not have, occurred to date, we found
68.4% of such predictions to be correct when based on the standard predictors, and 68.5% when serum YKL-40 was added as a
predictor. Equivalent results were obtained with c-statistics.
Conclusions-—Higher serum YKL-40 was independently associated with an increased risk of adverse cardiovascular outcomes and
mortality. Addition of YKL-40 did not improve risk prediction in patients with stable coronary artery disease.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00121550. ( J Am Heart Assoc. 2020;9:
e014634. DOI: 10.1161/JAHA.119.014634.)
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T he desire to better assess prognosis in patients withcardiovascular disease (CVD) and further advance the
understanding of the underlying atherosclerotic process has
prompted the emergence of numerous potential CVD
biomarkers. Many candidates have demonstrated consistent
association with standard CVD outcome measures. Nonethe-
less, auxiliary predictive potential in addition to that offered by
standard available clinical characteristics is in many cases
absent or unclear, hindering translation of results into specific
changes in patient management strategies.1–3 However, in
addition to possible utility in risk prediction, biomarker studies
may unravel new key factors in CVD pathogenesis such as
proinflammatory effectors, and ultimately help identify new
potential upstream treatment targets.4,5
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YKL-40, also known as chitinase-3-like-1, is an inflamma-
tory biomarker which has gathered increasing evidence during
the past 2 decades.6 It is considered an acute-phase protein
and has been specifically linked to the inflammatory process
in the atherosclerotic plaque,7 diseases of extracellular
remodeling and fibrosis,8 angiogenesis and regulation of
proinflammatory cascades.9,10 YKL-40 has recently been
associated with development of hyperlipidemia and ischemic
stroke in a study of almost 100 000 individuals from the
general population,11 and it has been studied as a risk marker
in both atherosclerotic development and CVD outcome
prediction in patients with acute coronary syndrome and
stable coronary artery disease (CAD).12–14
In the present study we assess the power of YKL-40 as a
predictor of cardiovascular outcomes and death in a cohort of
stable CAD patients using 10-year follow-up data obtained
from the CLARICOR (Effect of Clarithromycin on Mortality and
Morbidity in Patients with Ischemic Heart Disease) trial.15 This
study adds to prior reports on YKL-40 by extending follow-up
duration to 10 years, and appraising the potential clinical
translation of YKL-40 measurement using reclassification
analysis.16–18 All analyses were performed according to a
previously published statistical analyses plan.19,20
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Trial Design and Patients
The CLARICOR trial was an investigator-initiated, randomized,
placebo-controlled, multicenter superiority trial including
patients with stable CAD. A total of 13 702 patients aged 18
to 85 years who had a discharge diagnosis of myocardial
infarction, angina pectoris, percutaneous transluminal coronary
angioplasty, or coronary artery bypass surgery during 1993 to
1999 and were alive in August 1999 were invited by letter for a
14-day trial of clarithromycin versus placebo.15 Of these, 6116
accepted the invitation: 177 refused to participate, and 1567
were excluded while 4372 were randomized by a central
algorithm in a 1:1 ratio to clarithromycin versus placebo.
Patients were non-hospitalized and stable at trial inclusion.
Baseline data were obtained from the hospital files and
patient interviews at 6 cardiology clinics covering the
Copenhagen area, and participants were followed up through
Danish population registries. Exclusion criteria were presence
of the following conditions: (1) acute myocardial infarction or
unstable angina pectoris within the previous 3 months; (2)
percutaneous transluminal coronary angioplasty and coronary
bypass surgery within the previous 6 months; (3) impaired
renal or (4) hepatic function; (5) congestive heart failure (New
York Heart Association IV classification of heart failure); (6)
active malignancy; (7) absence of capacity to manage own
affairs, and (8) breastfeeding or possible pregnancy.
Participants were followed up for 10 years on average
from the end of treatment in October 1999 to April 2000 until
December 31, 2009. The follow-up data set was solely based
on register excerpts.
The main result of the CLARICOR trial was that clarithromycin
increased the risk of cardiovascular and all-cause death.15,21–23
The present study is a prognostic analysis focused on the placebo
groupwhichmay be considered a representative sample of stable
CAD patients, ie, not treated with clarithromycin. For corrobora-
tion and discovery, results in the clarithromycin-treated patient
group are similarly summarized.
Baseline Data and Predictors
Enrollment interviews at baseline provided smoking status,
current medication, presence of hypertension and diabetes
mellitus, while further data about sex, age, and cardiovascular
history (presence of previous acute myocardial infarction) were
obtained through local hospital files. Blood samples were
obtained just before randomization and immediately frozen at
80°C. Biochemical measurements on plasma included lipopro-
teins, high-sensitivity C-reactive protein (hs-CRP, mg/L)24 and
estimated glomerular filtration rate (mL/min) using creatinine.25
The above-mentioned baseline variables and quantities are
collectively referred to as “standard predictors,” see Table 1
and Statistical Analyses section below.
YKL-40 Analysis
In 4298 (98%) of the included patients’ serum was available
for YKL-40 determination, divided between 2163 in the
Clinical Perspective
What Is New?
• In patients with stable coronary artery disease, higher YKL-
40 is significantly related to cardiovascular events and
mortality over 10 years of follow-up after adjustment for
standard predictors and high-sensitivity C-reactive protein,
possibly reflecting high-risk atherosclerotic progression and
inflammation.
What Are the Clinical Implications?
• In reclassification analysis YKL-40 did not improve prog-
nostic accuracy compared with predictions based only on
standard predictors, and the value of measuring YKL-40 to
support clinical decision making appears limited.
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placebo group and 2135 in the clarithromycin group. Serum
concentrations were determined in duplicates by a commer-
cial ELISA (Quidel, San Diego, CA, USA) using streptavidin-
coated microplate wells, a biotinylated-Fab monoclonal
capture antibody, and an alkaline phosphatase-labeled poly-
clonal detection antibody. The recovery is 102%, detection
limit 20 mg/L, intra-assay coefficient of variation 5.0%, and
inter-assay coefficients of variation are <5.4% (low control)
and <6.7% (high control) in the 127 ELISA kits used for the
analysis of the 4298 samples.
Outcomes
Information about the underlying cause of death was obtained
from the National Register of Causes of Death26; The Danish
National Patient Register covering all somatic hospital
admissions provided hospitalization data.27 The Danish 10-
digit central person registration number is used at all contacts
with the healthcare system, and somatic hospital contact
cannot be completed without a diagnosis based upon the
International Classification of Diseases, Tenth Revision (ICD-
10) and subsequent notification of the National Patient
Register. All registers have coverage close to 100%.
For each recorded main diagnosis and for each underlying
cause of death, we classified the outcome into disjoint and
exhaustive categories28,29: Acute myocardial infarction (ICD
codes I21.0–I23.9), unstable angina pectoris (ICD codes I20.0
and I24.8–I24.9), both ischemic and hemorrhagic cerebrovas-
cular disease (ICD codes I60.0–I64.9 and G45.0–G46.8),
other cardiovascular diseases (ICD codes I00.0–I99.9, unless
already covered), and non-cardiovascular disease (ICD codes
A00.0–T98.3, unless already covered).
We constructed a composite outcome composed of acute
myocardial infarction, unstable angina pectoris, cerebrovas-
cular disease, or all-cause death during follow-up.
Statistical Analyses
A detailed description of the predefined statistical analysis
plan for selected cardiovascular biomarkers based on the
CLARICOR trial cohort, the Predictors for major cardiovascular
outcomes in stable ischemic heart disease (PREMAC) proto-
col, has formerly been published.19 All primary analyses were
performed on placebo group data because it was previously
shown that clarithromycin had a significant and harmful effect
on patient prognosis21; however, all analyses have additionally
been performed in the clarithromycin group.
To fulfill linearity assumption YKL-40/lg per L was log-
transformed. We examined the adjusted hazard ratio (HR) per
unit increase in ln(YKL40/lg per L).
We used Cox proportional hazards regression models
supplemented by Breslow estimation of the baseline hazard to
study the association between all the above-mentioned
standard predictors and YKL-40 as covariates, and the
composite outcome. The associations were examined in
univariate analysis, and in analysis adjusted for all standard
predictors. Model assumptions were tested using Bonferroni
adjusted thresholds for significance, and all covariate analy-
ses were stratified by center. In exploratory sub-analyses, the
association with the individual outcomes was also investi-
gated.
Entry information in the CLARICOR trial had virtually no
missing data, while 9.4% of patients had ≥1 laboratory tests
missing. The Little test was applied to decide whether
multiple imputation or complete case analyses should be
used, and after obtaining P=0.93 complete case analysis
was used.
To examine the predictive improvement obtainable with
YKL-40, we applied 2 different reclassification analysis
approaches. In the first analysis we read off the predicted
Cox-Breslow survival curve of each patient at 3 years of
follow-up and checked the likely outcome against the
patient’s actual course. If the patient’s actual status (still
event-free or not) was also the status predicted to be more
likely, the prediction was classified as “true favorable” (or
“true unfavorable”). This analysis, first based on the standard
predictors, was then repeated with YKL-40 included as a
predictor. Analogous results based on raw Kaplan-Meier
curves (no individual predictors) are reported for compari-
son. The 6- and 9-year status was similarly analyzed.
Secondly, we present a receiver operating characteristic
(ROC) analysis of the Cox-Breslow risks applied to the same
time window 0-to-9 years. Conventional “observed” ROCs
are plots of cumulative events against the cumulative event-
free contingency, with cumulation from large to small
estimated risks. The corresponding “predicted” ROC is
based on cumulating the predicted risks. The area under
the curves (or c-index) estimates the pairwise concordance
rate between risks and outcomes. To reward correct
prediction of time of event, we further determined a
“dynamic” c-index, alias risk concordance within any pair
of participants whose event order was deducible from the 9-
year data window.
All analyses were performed using SAS V.9.4
Ethics
The study was performed in accordance with the Helsinki
Declaration and was approved by the local ethics
committee (KF 01-076/99), the Danish Medicines Agency
(2612-975), and the Danish Data Protection Agency (1999
1200-174). All participants gave written informed consent,
after receiving oral and written information about the
study.
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Results
Study Population and Prognostic Importance of
Standard Predictors
Patients randomized to placebo and clarithromycin amounted
to 2200 and 2172, respectively.
The median serum concentration of YKL-40 in all patients
was 110 lg/L (25th/75th percentiles 75/166 lg per L).
Table 1 presents baseline characteristics of the placebo
and clarithromycin groups, illustrating that randomization was
apparently successful with equal distribution of the studied
quantities.
At 3 years follow-up in the placebo group 1826 (83.0%)
patients had not experienced a composite outcome, and 2073
(94.3%) were still alive. At 6 years the respective numbers were
1261 (57.3%) free of the composite outcome and 1758 (79.9%)
still alive, and at 9 years the numberswere969 (44.9%) and1487
(67.6%). See Table S1 for cumulative events specified by subtype.
When all standard predictors were included in the model,
smoking status, diabetes mellitus, long-lasting nitrate medi-
cation, digoxin, and interaction between age and time were
associated with a higher risk of the composite outcome, while
a higher glomerular filtration rate was associated with a lower
HR (Table S2).
Table 1. The Distribution of Standard Predictors in the Placebo Group and in the Clarithromycin Group of the CLARICOR Trial
Standard Predictors Placebo Patients (n=2200) Clarithromycin Patients (n=2172)
Demographics and history
Sex (male), n (%) 1518 (69.0) 1514 (69.7)
Age/y, mean (SD) 65.2 (10.4) 65.4 (10.3)
Smoking status (smoking, ex-smoker, never smoked), n (%) Smokers, 753 (34.2) Smokers, 819 (37.6)
Ex-smokers, 1011 (46.0) Ex-smokers, 982 (45.2)
Never smoked, 435 (19.8) Never smoked, 371 (17.1)
Hypertension, n (%) 883 (40.2) 878 (40.4)
Diabetes mellitus, n (%) 337 (15.3) 341 (15.7)
Previous AMI, n (%) 1494 (67.9) 1470 (67.7)
Medication at randomization
Aspirin, n (%) 1937 (88.1) 1902 (87.6)
Beta-blocker, n (%) 681 (31.0) 653 (30.1)
Calcium antagonist, n (%) 772 (35.1) 755 (34.8)
ACE inhibitor, n (%) 577 (26.3) 604 (27.8)
Long-lasting nitrate, n (%) 457 (20.8) 453 (20.9)
Diuretics, n (%) 773 (35.2) 762 (35.1)
Digoxin, n (%) 126 (5.7) 154 (7.1)
Statins, n (%) 904 (41.1) 896 (41.3)
Antiarrhythmic drugs, n (%) 51 (2.3) 55 (2.5)
Biochemical predictors
CRP mg/L mean (SD), n* 2.80 (3.06) 2159 2.91 (3.16) 2128
ApoA1 mg/dL mean (SD), n 1.70 (0.34) 2076 1.70 (0.36) 2041
Apolipoprotein B mg/dL mean (SD), n 1.17 (1.31) 2075 1.16 (1.31) 2040
Cholesterol-HDL mg/dL mean (SD), n 39.44 (12.37) 2074 39.44 (12.37) 2039
Cholesterol-LDL mg/dL mean (SD), n 99 (27.84) 2079 98.6 (28.23) 2044
Cholesterol mg/dL mean (SD), n 218.1 (47.18) 2075 215.78 (47.18) 2039
Triglyceride mg/dL mean (SD), n 184.23 (150.58) 2078 179.8 (148.8) 2040
Glomerular filtration rate (mL per min) mean (SD), n 71.8 (19.2) 2079 72.1 (19.2) 2044
ACE indicates angiotensin-converting enzyme; AMI, acute myocardial infarction; CLARICOR, Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease;
CRP, C-reactive protein; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*The value of n varies because the laboratory tests have missing values.
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Follow-Up Results
Table 2 shows the HRs for YKL-40 for each specified
outcome, the composite outcome, and all-cause death per
unit increase in ln(YKL-40/lg per L). YKL-40 was significantly
associated with the composite outcome and all-cause mor-
tality when used alone, and in combination with all standard
predictors.
Prognostic Improvement
Table 3 shows the true favorable and unfavorable predictions
obtained when using the Cox model for both the composite
outcome and all-cause mortality. Percentages are correct
predictions out of total number of predictions (total predic-
tions=5970, 3 per patient unless dropout). Without any
individual data being considered, 63.2% of predictions were
correct for the composite outcome, and with addition of
standard predictors 68.4% of predictions were correct. With
the further addition of YKL-40 68.5% of predictions were
correct. Turning to all-cause mortality (lower part of the table),
we see a similar pattern with no visible improvement
ascribable to YKL-40.
Table 4 and Figure summarize the ROC analysis. For
prediction of a composite outcome, the area under the ROC
increases from 0.711 to 0.713 when log(YKL40) is added to
the “standard predictors.” In the figure the 2 observed ROCs
practically coincide with each other, as well as their predicted
counterparts (omitted). The “dynamic” c-index values are
smaller as prediction of event times is more difficult, but the
gains of introducing YKL-40 are similar.
Results in the Clarithromycin-Treated Group
Both the direction and magnitude of relations between the
standard predictors and YKL-40 and the investigated out-
comes in the clarithromycin group were largely equivalent to
those obtained in the placebo group outlined above
(Table S3).
Similarly, the net increase in true prediction percentages
when adding YKL-40 to the standard predictors was from
69.1% to 69.5% for the composite outcome, and from 83.0%
to 83.1% for all-cause death (Table S4).
Discussion
Main Findings
In the placebo group of the CLARICOR trial in patients with
stable CAD, elevated levels of YKL-40 were significantly
associated with increased risk of cardiovascular outcomes
and all-cause mortality over 10 years of follow-up in both
univariate and multiple adjusted survival analyses. The ability
to predict future CVD outcomes and mortality was not
improved following addition of YKL-40 to the standard model.
Results were similar in the clarithromycin-treated patient
group.
Study Strengths and Limitations
The principal strengths of the present study are the patient
population size, the 10-year long follow-up in registers with no
loss to follow-up of events and the detailed characterization of
patients. In addition to reporting HRs, the study provides
insight into the potential clinical implementation of YKL-40 as
a prognostic biomarker by evaluating obtained prediction
improvement when adding YKL-40 to standard predictors.
Limitations include the lack of certain baseline characteris-
tics, eg, body mass index and systolic blood pressure. Data on
previous peripheral artery disease or ischemic stroke were not
available for analysis. As a consequence, we did not have data
on all variables included in contemporary risk algorithms for
secondary prevention such as American College of Cardiology/
American Heart Assocation 2018 guidelines or the TIMI Risk
Score for Secondary Prevention.30,31 Further, we did not have
access to longitudinal monitoring of the biomarker.
Atherosclerosis, Inflammation, and YKL-40
In the CLARICOR cohort, we have previously reported that
YKL-40 levels were significantly higher in patients with age
≥60 years, hypertension or diabetes mellitus, and in patients
who used calcium antagonists, angiotensin-converting
enzyme inhibitors, long-lasting nitrates, diuretics, or digoxin.18
The present study shows that most of these risk factors were
also associated with the composite outcome in univariate
analyses (Table S2). Further, the association between YKL-40
and the composite outcome was attenuated after multivariate
adjustment for the baseline standard predictors (Table 2). Our
results suggest that the presence of risk factors, and
comorbidities requiring medical therapy, may initiate a
progression in the atherosclerotic process ultimately leading
to CVD outcomes, and concomitant or co-incident YKL-40
stimulation. YKL-40 may therefore be an inflammatory
biomarker which reflects plaque development primarily
elicited by risk factor presence in itself.4,32
Activated macrophages and neutrophils secrete YKL-40 in
various disease tissues characterized by inflammation, extra-
cellular remodeling, and fibrosis.33 It is an angiogenic
stimulator, and has been shown to maintain connective
tissue structure and attenuate the inflammatory response in
the presence of tumor necrosis factor-alpha stimulation.34
Macrophages located deep in the developing atherosclerotic
plaque exhibit the highest expression of YKL-40.7
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Mendelian randomization studies have suggested that
genetically elevated YKL-40 levels do not play a causative role
in the development of CVD,11,35 but this finding does not rule
out the possibility that YKL-40 could play a role in disease
progression after diagnosis, and whether alteration of YKL-40
function might improve outcomes in atherosclerotic disease
has not yet been determined. An experimental study has
shown that YKL-40 attenuates inflammasome activation,
thereby acting as an anti-inflammatory effector, while YKL-
40 inhibition with chitosan led to increased inflammasome
activity.10
Comparison With Other Cardiovascular Disease
Studies
Previous studies in varied CVD patient groups and the general
population have evaluated the possible association between
YKL-40 levels, diagnostic tests, and prognosis.
In acute coronary syndrome patients, several studies have
demonstrated a significant increase in YKL-40 level immedi-
ately following acute coronary events which persists regard-
less of revascularization. YKL-40 was associated with a
detrimental prognosis and persisting left ventricular dysfunc-
tion.13,36,37 In addition, a recent study reported an overall
association between degree of angiographic atherosclerosis
severity and YKL-40 level.38 These results suggest a possible
increase in plasma YKL-40 synchronous with atherosclerotic
progression and coronary events, which persists and may
predict a detrimental outcome in acute coronary syndrome
patients.
In stable CAD patients, YKL-40 level was significantly
associated with number of diseased coronary vessels with
>50% stenosis in 1 study,39 and has been linked to both
higher SYNTAX score, poor development of coronary collat-
erals and myocardial perfusion defects.14,16,40,41 In 313
patients with stable CAD, YKL-40 performed slightly better
Table 2. Hazard Ratios of YKL-40 When Used Alone and Adjusted for the Rest of the Standard Predictors in the Placebo Group of
the CLARICOR Trial
Outcome
YKL-40 Used Alone YKL-40 Adjusted for Standard Predictors
HR 95% CI of HR P Values HR 95% CI of HR P Values
Unstable angina pectoris 1.09 0.93 to 1.29 0.28 0.99 0.83 to 1.19 0.94
Acute myocardial infarction 1.36 1.18 to 1.56 <0.0001 1.19 1.02 to 1.40 0.028
Cerebrovascular disease 1.18 0.99 to 1.40 0.06 0.95 0.78 to 1.16 0.64
Cardiovascular death 1.67 1.44 to 1.93 <0.0001 1.23 1.03 to 1.47 0.025
Composite outcome 1.35 1.24 to 1.47 <0.0001 1.13 1.03 to 1.24 0.013
All-cause mortality 1.76 1.59 to 1.95 <0.0001 1.32 1.17 to 1.49 <0.0001
Composite outcome including acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, or all-cause mortality. HR indicates hazard ratio; CLARICOR, Effect of
Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease.
Table 3. The Types and Numbers of Correct Predictions Obtained From the Cox Proportional Hazards Model
Prediction Type No Covariates SP Included SP Plus YKL-40 Included
Composite outcome
True favorable predictions, n (%) 2658 (44.5) 2910 (48.7) 2909 (48.7)
True unfavorable predictions n, (%) 1115 (18.7) 1174 (19.7) 1179 (19.7)
Total number of true predictions, n (%) 3773 (63.2) 4084 (68.4) 4088 (68.5)
All-cause mortality
True favorable predictions, n (%) 4768 (79.9) 4585 (76.8) 4582 (76.7)
True unfavorable predictions, n (%) 0 (0)* 392 (6.57) 398 (6.67)
Total number of true predictions, n (%) 4768 (79.9) 4977 (83.4) 4980 (83.4)
For comparison results without covariates, with standard predictors included, and with YKL-40 included, are shown. For each patient at time (T) equal to 3, 6, and 9 years and using the
patient’s individual survival curve the predicted outcome (patient “alive at T” (favorable outcome) compared with patient “not alive at T” [unfavorable outcome]) was read off the survival
curve and the results compared with the observed outcome. When no covariates were included in the model, this coincides with the Kaplan-Meier survival curve which was used to
calculate the predictions. To allow for the fact that age violated the proportional hazard assumption we stratified by age categories in addition to center and excluded age from the
covariates. Total predictions=5970, n (%)=true favorable predictions/total predictions. SP indicates standard predictors.
*As total mortality is <50%, all predictions are automatically favorable (and 79.9% of them pertain to a so far survivor).
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than hs-CRP in predicting re-stenosis after percutaneous
transluminal coronary angioplasty.42 Our group has published
a large prognostic study in stable CAD patients from the
entire CLARICOR cohort which found that YKL-40 level was
associated with all-cause and cardiovascular mortality, and
this association remained significant after adjustment for hs-
CRP and NT-proBNP (N-terminal pro-B-type natriuretic pep-
tide) levels.17,18
In healthy individuals, Ridker et al43 performed a nested
case-control study in a cohort of >20,000 women and found
that YKL-40 predicted thromboembolic stroke with a 40%
increase in odds ratio per quartile. Another large
observational study investigating YKL-40 in almost 100,000
individuals from the Danish general population found that
individuals in the 91% to 100% highest YKL-40 percentile had
a significantly increased risk for ischemic cerebrovascular
disease and ischemic heart disease compared with the 0% to
33% percentile over a 36-year follow-up period.11
Clinical Implications
Although the main results in the present study underline a
connection between YKL-40 and CVD severity and outcomes,
we also found that addition of YKL-40 to standard predictors
did not alter outcome prediction ability to a noteworthy
degree. Morrow et al1 have proposed criteria for the potential
translation of a biomarker to clinical implementation, ie, (1)
can the clinician measure it, (2) does it add new information,
and (3) does it help the clinician manage patients? For YKL-
40, existing evidence does not fulfill the last 2 of the 3 criteria
at present.2,44 Direct comparisons with established prediction
models when evaluating predictive benefit of a biomarker
would appear especially relevant in ischemic heart disease,
where several clinical scores such as Framingham Risk
Score45 and GRACE (Global Registry of Acute Coronary
Events) Score46 are already used in the general population
and acute coronary syndrome patients, respectively. Our
results suggest that YKL-40 is not an important prognostic
biomarker when taking baseline risk factors into account.
Candidate protein biomarkers in CVD research are numer-
ous, and as a result several attempts have been made to
develop stringent methodological approaches to biomarker
evaluation.47,48 Significant association between the biomarker
and the outcome of interest is a necessary requirement, but
biomarker usefulness should also be evaluated with statistical
methods which directly convey the absolute changes in
patient categorization. Proposed statistical indices of valuable
reclassification include the ROC and more recently the net
reclassification index (NRI). NRI may however be more
unreliable and misleading than initially thought with the risk
of yielding false-positive NRI statistics.49,50
The majority of candidate CVD biomarkers lack sufficient
reclassification assessment, and even some of the most
thoroughly investigated candidate biomarkers have failed to
exhibit clinically meaningful reclassification potential.51 As an
example, value of hs-CRP measurement has been evaluated
against Framingham Risk Score: The increases in c-statistic
and NRI were diminutive and clinically irrelevant,51 and in a
large pooled analysis of 52 prospective studies, the addition
of hs-CRP to standard risk factors failed to increase the c-
index or NRI.52 A White Paper evaluating the role of hs-CRP in
CVD did not find that current evidence supported the use of
hs-CRP in risk prediction, and this recommendation was
specifically based on a lack of reclassification improvement.53
Figure. Receiver operating characteristics pertaining to the
composite outcome within the 9-year data window. Standard
predictors only: fat curve; ln(YKL40) added: thin curve. For area
under curve see Table 4.
Table 4. c Index of 9-Year Outcomes
Binary c (AUC),
Observed
(Predicted)
Dynamic c,
Observed
Composite outcome (1115 events)
YKL40 included 0.713 (0.708) 0.641
Standard predictors only 0.711 (0.707) 0.640
All-cause death (644 deaths)
YKL40 included 0.795 (0.796) 0.741
Standard predictors only 0.792 (0.793) 0.737
Composite outcome including acute myocardial infarction, unstable angina pectoris,
cerebrovascular disease or all-cause mortality. AUC indicates area under curve.
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The findings for hs-CRP resemble our findings for YKL-40, ie, a
multivariate-adjusted significant HR for cardiovascular out-
comes which simultaneously demonstrates little benefit.
CLARICOR Main Findings and YKL-40
The CLARICOR study main finding of an increased risk of CVD
outcomes in patients treated with clarithromycin was unex-
pected.15 In the present YKL-40 study, HRs and reclassifica-
tion results in the placebo group versus the clarithromycin
group were similar. This study does not contribute new
information which may help explain the different event rates
observed in the CLARICOR trial.
Conclusions
We have shown that YKL-40 is associated with adverse CVD
outcomes and death independently of established risk factors
in patients with stable CAD. Improvement in reclassification
after addition of YKL-40 to standard predictors was negligible.
Elevated YKL-40 levels may signify high-risk atherosclerosis
and ongoing inflammation in the atherosclerotic plaque in
stable CAD patients with cardiovascular risk factors. Whether
targeted anti-inflammatory therapy could carry a prognostic
benefit in patients with elevated YKL-40 levels remains to be
investigated.
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Table S1. Cumulative number of outcomes, by subtype. 
 
      
   
Time period AMI UAP Ce-VD CV-death Death 
year≤ 1 46 68 38 28 52 
year≤ 2 128 121 76 56 111 
year≤ 3 181 175 109 88 171 
year≤ 4 232 228 145 127 251 
year≤ 5 270 262 174 151 314 
year≤ 6 310 286 203 183 388 
year≤ 7 344 305 227 223 470 
year≤ 8 382 325 247 271 573 
year≤ 9 414 341 278 302 644 
 
AMI, acute myocardial infarction; UAP, unstable angina pectoris; Ce-VD; cerebrovascular disease, CV-death; cardiovascular death 
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Table S2. Composite outcome hazard ratios (HR) of standard predictors when used alone and 
adjusted for the rest of the standard predictors in the placebo group of the CLARICOR trial. 
 
       
 
 
Single predictor examined in the 
model (stratified by center)  
All standard predictors in the 
model (stratified by center)  
Standard predictors  HR  
95% CI of 
HR  P values  HR  
95% CI of 
HR  P values  
Demographics and history        
Sex (male=1) 1.004 0.889 to 1.134  0.95 1.150 1.005 to 1.315  0.042  
Age/year 1.024 1.013 to 1.034  <0.0001  1.013 1.001 to 1.025  0.030  
Age∙time/year∙year 1.00374 1.002 to 1.006  0.0004  1.004 1.002 to 1.006  <0.0001  
Smoking status (ex-smoker 
compared to never smoking) 1.203 1.026 to 1.410  0.0062  1.210 1.025 to 1.428  <0.0001  
Smoking status (smoking 
compared to never smoking) 1.309 1.110 to 1.545   1.547 1.300 to 1.842   
Hypertension, Y/N 1.105 0.985 to 1.239  0.090  0.991 0.870 to 1.129  0.89 
Diabetes, Y/N 1.318 1.133 to 1.533  0.0003  1.261 1.076 to 1.480  0.0043  
Previous AMI, Y/N 1.169 1.033 to 1.324  0.014  1.151 1.012 to 1.308  0.032  
Medication at randomization       
Aspirin, Y/N 0.978 0.820 to 1.165  0.80 1.021 0.852 to 1.225  0.82 
Beta-blocker, Y/N 1.010 0.893 to 1.141  0.88 1.013 0.888 to 1.155  0.85 
Calcium antagonist, Y/N 1.232 1.095 to 1.385  0.0005  1.121 0.982 to 1.279  0.090  
ACE inhibitor, Y/N 1.246 1.099 to 1.412  0.0006  1.054 0.916 to 1.213  0.46 
Long-lasting nitrate, Y/N 1.738 1.527 to 1.978  <0.0001  1.348 1.172 to 1.551  <0.0001  
Diuretics, Y/N 1.613 1.437 to 1.810  <0.0001  1.180 1.030 to 1.352  0.017  
Digoxin, Y/N 2.212 1.805 to 2.711  <0.0001  1.576 1.269 to 1.957  <0.0001  
Statins, Y/N 0.746 0.663 to 0.839  <0.0001  0.883 0.769 to 1.014  0.077  
Antiarrhythmic drugs, Y/N 1.119 0.763 to 1.642  0.56 0.924 0.627 to 1.362  0.69 
Biochemical predictors        
Log (CRP/mg/L) 1.171 1.113 to 1.232  <0.0001  1.070 1.014 to 1.480  0.014  
ApoA1 mg/dL 0.905 0.764 to 1.072  0.25 0.707 0.516 to 0.969  0.031  
Log (ApoB/mg/dL) 1.165 0.938 to 1.447  0.17 0.826 0.413 to 1.651  0.59 
Cholesterol-HDL mmol/L 0.954 0.794 to 1.147  0.62 1.104 0.714 to 1.708  0.66 
Cholesterol-LDL mmol/L 1.027 0.948 to 1.112  0.52 0.912 0.751 to 1.107  0.35 
Log(cholesterol/mmol/L) 1.247 0.940 to 1.654  0.13 1.786 0.577 to 5.525  0.31 
Log(triglyceride/mmol/L) 1.024 0.919 to 1.141  0.67 1.030 0.878 to 1.208  0.72 
Glomerular filtration rate 
(GFR/mL/min) 0.985 0.982 to 0.988  <0.0001  0.995 0.991 to 0.999  0.0084  
Composite outcome including acute myocardial infarction, unstable angina pectoris, cerebrovascular disease and all-cause death. 
Time is years since randomisation, whereas age is age at randomization. HR = hazard factor associated with 1 unit increase, log 
values being natural logs.  
AMI, acute myocardial infarction; ACE, angiotensin-converting enzyme; CRP, C-reactive protein; Apo, apolipoprotein; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; N, hypertension is not present; Y, hypertension is present. 
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Table S3. Hazard ratios of YKL-40 when used alone and when adjusted for standard 
predictors in the clarithromycin group of the CLARICOR trial. 
 
       
 
 YKL-40 used alone  YKL-40 adjusted for standard predictors 
Outcome HR  95% CI of HR  P values  HR  95% CI of HR  P values  
Unstable angina pectoris 1.10 0.93 to 1.29 0.26 1.05 0.88 to 1.26 0.58 
Acute myocardial infarction 1.25 1.08 to 1.95 0.003 1.05 0.89 to 1.25 0.38 
Cerebrovascular disease 1.26 1.07 to 1.49 0.007 1.05 0.87 to 1.27 0.27 
Cardiovascular death 1.67 1.44 to 1.92 <0.0001 1.27 1.07 to 1.51 0.007 
Composite outcome 1.38 1.27 to 1.50 <0.0001 1.16 1.05 to 1.28 0.003 
All-cause mortality 1.67 1.51 to 1.84 <0.0001 1.28 1.14 to 1.44 <0.0001 
Composite outcome including acute myocardial infarction, unstable angina pectoris, cerebrovascular disease and all-cause mortality. 
HR, hazard ratio. 
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Table S4. The types and numbers of correct predictions obtained from the Cox proportional 
hazards model in the clarithromycin group of the ClARICOR trial. 
   
 
 Composite outcome  
Prediction type Standard predictors included (SP) SP plus YKL-40 included 
True favorable predictions N (%)* 2763 (46.3) 2772 (46.4) 
True unfavorable predictions N (%) 1362 (22.8) 1376 (23.0) 
Total number of true predictions N (%) 4125 (69.1) 4148 (69.5) 
   
 
All-cause mortality 
 
 Standard predictors included (SP) SP plus YKL-40 included 
True favorable predictions N (%) 4472 (74.9) 4472 (74.9) 
True unfavorable predictions N (%) 484 (8.11) 488 (9.78) 
Total number of true predictions N (%) 4956 (83.0) 4960 (83.1) 
 
For comparison results with standard predictors included, and with YKL-40 included, are shown 
For each patient at time (T) equal to 3, 6 and 9 years and using the patient’s individual survival curve the predicted outcome (patient 
‘alive at T’ (favorable outcome) compared with patient ‘not alive at T’ (unfavourable outcome)) was read off the survival curve and 
the results compared with the observed outcome. When no covariates were included in the model, the Kaplan-Meier survival curve 
was used to calculate the predictions.  
To allow for the fact that age violated the proportional hazard assumption we stratified by age categories in addition to center and 
excluded age from the covariates. 
Total predictions = 5971, N(%) = true favorable predictions / total predictions 
 
D
ow
nloaded from
 http://ahajournals.org by on May 5, 2020
